A diagnosis of vulvovaginal atrophy (VVA) in breast cancer survivors is associated with a significant increase in the burden of illness and social costs, according to an Italian Delphi Panel in the journal Supportive Care in Cancer. These findings are primarily due to a rise in comorbidities and resource utilization, but adequate treatment might reduce the impact of the condition.
New research indicates having at least one symptom of vulvovaginal atrophy is linked to significant impaired sexual function for postmenopausal women.
Published research from Sexually Transmitted Diseases indicates a woman’s risk of vulvovaginal candidiasis could be increased by certain personal behaviors as well as the composition of her vaginal microbiota.
Although nearly half of postmenopausal women reported having vulvovaginal symptoms (VVS), only a minority discussed their symptoms during a well-woman visit with a primary care provider or gynecologist, according to recent survey analysis.
The safety and efficacy of targeting vulvovaginal tissues are the topic of this committee opinion.
The experimental agent TX-004HR effectively improved the vaginal mucosa of postmenopausal women with vulvovaginal atrophy (VVA) and reduced moderate-to-severe dyspareunia and vaginal dryness compared to placebo, according to results of a trial.
A small study shows that treatment with CO2 laser induces histological changes in the epithelium and lamina propria that may result in improvement in symptoms associated with vulvovaginal atrophy (VVA).
Results of a randomized clinical trial (RCT) suggest that over-the-counter moisturizer may be just as effective as vaginal estrogen tablets for treatment of vulvovaginal symptoms (VVS) in postmenopausal women. Plus: Does a Mediterranean diet help protect bones in postmenopausal women? Also: Metformin, an oral diabetes medication, seems to reduce the likelihood of late miscarriage and premature birth in women with polycystic ovary syndrome (PCOS), according to results of a multicenter study.
